Precisio Biotix Therapeutics (“Precisio”) is a US-incorporated
industry leader in precision antibacterial biological solutions;
specifically, the identification and development of lysin, amurin, and phage solutions and related delivery technologies to combat
bacterial infections and address related unmet medical needs.
Precisio is a platform-plus-product drug discovery and
development company, with both Rx and consumer products. Precisio can provide low-cost antibacterials for most of the world.
Treating multiple bacterial conditions utilizing first or best-in-class lysins with an emphasis on lung, vaginal, and topical treatments.
>More
Preventing and treating AMR resistant topical infections utilizing novel sustained release phage spray and patch systems.
Lead product is for the treatment and prevention of topical AMR pressure injury infections.
>More
Antibiotic Resistance - The Need for New Treatments
According to WHO, if we do not take significant action, we will enter a post-antibiotic era in which a common infection and minor injury can be life-threatening. It is estimated that by 2050 more people will die from infection than from cancer.
>More
Contact Us
Precisio Biotix Therapeutics
Email to Director of Investor Relations: shencj@precisiobiotix.com
